Loading
A phase 1 trial of PTX-912 run by Proviva Therapeutics, Inc., now recruiting.
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06190886 by Proviva Therapeutics, Inc., with 26 participants planned, started 2024-06-11, primary completion expected 2026-05-14. Conditions recorded: Advanced Cancer, Solid Tumor, Metastatic Cancer. Interventions recorded: PTX-912.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/